Resume-aware faculty matching

Find professors who actually fit you

Upload your resume. Four AI agents analyze your background, rank the faculty who fit, inspect their recent research, and help you draft outreach — grounded in their actual work, not templates.

Free to startNo credit cardCancel anytime
Top matches Balanced preset
Dr. Sarah Chen
Stanford · Interpretability · NLP
91
Dr. Marcus Holloway
MIT · Robotics · RL
84
Dr. Aisha Okonkwo
CMU · Fairness · HCI
82
Nova · Professor Researcher · re-ranking top 20…
William E. Bentley

William E. Bentley

· Robert E. Fischell Distinguished Professor, Director, Robert E. Fischell Institute for Biomedical Devices, Director, Maryland Technology Enterprise InstituteVerified

University of Maryland, College Park · Bioengineering

Active 1986–2026

h-index83
Citations27.9k
Papers71899 last 5y
Funding$30.2M2 active
See your match with William E. Bentley — sign in to PhdFit.Sign in

About

William E. Bentley is the Robert E. Fischell Distinguished Professor of Engineering and was the founding Chair of the Fischell Department of Bioengineering at the University of Maryland. He is the Inaugural Director of the Robert E. Fischell Institute for Biomedical Devices and also serves as the director of the Maryland Technology Enterprise Institute (Mtech). His academic appointments include the Department of Chemical and Biomolecular Engineering at the University of Maryland, College Park, and the Institute for Bioscience and Biotechnology Research. Since joining Maryland in 1989, Dr. Bentley has focused his research on developing molecular tools that facilitate the expression of biologically active proteins. His work includes deciphering and manipulating signal transduction pathways, particularly bacterial communication networks, to alter cell phenotypes. His laboratory develops strategies to open communication between devices and biological systems through the creation of biologically functional interfaces, contributing to fields such as biofabrication and bioelectronics. He has authored over 350 publications related to biomolecular and metabolic engineering, cell-cell communication, heterologous protein expression, and device/bio interfaces. Dr. Bentley has served on advisory committees for numerous agencies including NIH, NSF, DOD, DOE, FDA, and USDA, and has mentored more than 40 PhD students and 15 postdoctoral researchers, many of whom hold leadership roles in industry, government, and academia. He co-founded Chesapeake PERL, a protein manufacturing company based on insect larvae as mini bioreactors. His numerous awards include the SIM’s Schering-Plough Young Investigator Award, the Charles Thom Award of the SIMB, the Marvin Johnson Award of the BIOT Division in the ACS, and the AIChE’s FPB Division Award. He is a Fellow of the ACS, AAAS, and AIMBE, and an elected member of the American Academy of Microbiology.

Research topics

  • Biology
  • Computer Science
  • Chemistry
  • Computational biology
  • Engineering
  • Biochemical engineering
  • Materials science
  • Biological system
  • Biotechnology
  • Combinatorial chemistry
  • Chemical engineering
  • Bioinformatics
  • Genetics
  • Ecology
  • Organic chemistry
  • Evolutionary biology
  • Composite material
  • Cell biology
  • Nanotechnology

Selected publications

  • Su1514 GENETICALLY-PROGRAMMED ENHANCED BACTERIAL EXTRACELLULAR VESICLES REDUCE INFLAMMATION IN PRECLINICAL MODELS OF ACUTE BUT NOT CHRONIC COLITIS

    Gastroenterology · 2026-05-01

    article
  • Su1514 GENETICALLY-PROGRAMMED ENHANCED BACTERIAL EXTRACELLULAR VESICLES REDUCE INFLAMMATION IN PRECLINICAL MODELS OF ACUTE BUT NOT CHRONIC COLITIS

    Gastrointestinal Endoscopy · 2026-05-01

    article
  • BPS2026 – Redox control of phenazine biosynthesis via disulfide bond engineering of the PhzM methyltransferase

    Biophysical Journal · 2026-02-01

    articleSenior author
  • Genetically-programmed Hypervesiculation of <i>Lactiplantibacillus plantarum</i> Increases Production of Bacterial Extracellular Vesicles with Therapeutic Efficacy in a Preclinical Inflammatory Bowel Disease Model

    bioRxiv (Cold Spring Harbor Laboratory) · 2025-06-25 · 3 citations

    preprintOpen access

    Abstract Inflammatory bowel diseases (IBD) affect over 6 million people globally and current treatments achieve only 10-20% rates of durable disease remission. Bacterial extracellular vesicles (BEVs) from probiotic lactic acid bacteria (LAB) are a promising novel therapeutic with mechanisms holding potential to drive increased rates of durable disease remission, including immunomodulation and intestinal epithelial tissue repair. However, translation of these cell-secreted nanovesicles is limited by long standing biomanufacturing hurdles, especially low production yields due to low biogenesis rates from cells. Here, our goal was to identify a candidate probiotic LAB that produces BEVs effective in a preclinical mouse model of IBD, and then genetically engineer the LAB for at least 10-fold increased production yields of BEVs, thereby passing a critical production threshold. We identified Lactiplantibacillus plantarum as a candidate LAB producing BEVs effective in treating acute dextran sulfate sodium (DSS)-induced murine colitis, and with greater efficacy than BEVs from probiotic Escherichia coli Nissle 1917. We then genetically engineered a hypervesiculating L. plantarum strain by inducible expression of a peptidoglycan-modifying enzyme, resulting in a 66-fold increase in BEV productivity. Finally, we confirmed hypervesiculating L. plantarum BEVs were therapeutically effective in the acute DSS mouse model of colitis and found these BEVs were superior in reducing mucosal tissue damage compared to live L. plantarum cells. These findings demonstrate that BEVs from genetically engineered hypervesiculating strain of L. plantarum are a promising preclinical therapeutic candidate for IBD that overcomes historical biomanufacturing limitations of BEV therapeutics.

  • Author response for "3D Nanoprinting of PDMS Microvessels with Tailored Tortuosity and Microporosity via Direct Laser Writing"

    2025-02-25

    peer-review
  • Isolation and Characterization of Bacteria Associated with the Cultured Diatom Halamphora Sp.: Focus on Heavy Metal Resistance and Bioremediation Potential

    SSRN Electronic Journal · 2025-01-01

    preprintOpen access
  • Measuring oxidative stress by the iridium reducing capacity assay (Ir-RCA)

    Advances in Redox Research · 2025-03-28 · 2 citations

    articleOpen access

    • The Ir-RCA is a potential global measurement for oxidative stress. • The Ir-RCA measures stable features in a biological sample. • The Ir-RCA is more sensitive than other global antioxidant (reducing capacity) assays. • Ir-RCA measurements are "movable", allowing the measurement of dynamic responses to external stressors. Oxidative stress appears to act globally and span body systems (e.g., nervous, immune, and endocrine). Currently, there is no single, generally-accepted measurement of oxidative stress. Many possible measurement approaches focus on the bottom-up analysis of individual molecules (e.g., reactive species, antioxidants, hormones or signaling molecules) or combinations of molecules (e.g., proteomics or metabolomics). Efforts to develop a global measurement of oxidative stress often detect a sample's ability to reduce a metal-ion (e.g., iron or copper) or quench a free radical. Here, we review results from a recently-developed iridium-reducing capacity assay (Ir-RCA) and suggest that this method offers several key benefits as a potential measurement of oxidative stress. First, the Ir-RCA employs simple optical and/or electrochemical measurements that can be extended to high throughput formats. Second, the Ir-RCA appears to be more sensitive than alternative global antioxidant assays. Third, the Ir-RCA measures stable molecular features of a sample. Fourth, the Ir-RCA has been “validated” by showing statistically significant differences in persons diagnosed with schizophrenia ( N = 73) versus healthy controls ( N = 45). Fifth, the Ir-RCA measurement of oxidative stress is “movable”: psychosocial stressors can increase this measure of oxidative stress, while beneficial dietary interventions can decrease this measure of oxidative stress. Limitations and future directions for the Ir-RCA are discussed.

  • Genetically‐Programmed Hypervesiculation of <i>Lactiplantibacillus Plantarum</i> Increases Production of Bacterial Extracellular Vesicles with Therapeutic Efficacy in a Preclinical Inflammatory Bowel Disease Model

    Advanced Science · 2025-11-26

    articleOpen access

    Inflammatory bowel diseases (IBD) affect over 6 million people globally and current treatments achieve only 10-20% rates of durable disease remission. Bacterial extracellular vesicles (BEVs) from probiotic lactic acid bacteria (LAB) are a promising novel therapeutic with mechanisms holding potential to drive increased rates of durable disease remission, including immunomodulation and intestinal epithelial tissue repair. However, translation of these cell-secreted nanovesicles is limited by long standing biomanufacturing hurdles, especially low production yields due to low biogenesis rates from cells. Here, Lactiplantibacillus plantarum is identified as a candidate LAB producing BEVs effective in treating acute dextran sulfate sodium (DSS)-induced murine colitis with greater efficacy than BEVs from probiotic Escherichia coli Nissle 1917. Genetic engineering of L. plantarum to create a hypervesiculating strain via inducible expression of a peptidoglycan-modifying enzyme is shown to enable a 66-fold increase in BEV productivity. Finally, hypervesiculating L. plantarum BEVs are confirmed to be therapeutically effective in the acute DSS mouse model of colitis, with superior reduction of mucosal tissue damage compared to live L. plantarum cells. These findings demonstrate that BEVs from genetically engineered hypervesiculating strain of L. plantarum are a promising preclinical therapeutic candidate for IBD that overcomes historical biomanufacturing limitations of BEV therapeutics.

  • Yersinia pseudotuberculosis growth arrest during type-III secretion system expression is associated with altered ribosomal protein expression and decreased gentamicin susceptibility

    PLoS Pathogens · 2025-07-07 · 1 citations

    articleOpen accessCorresponding

    It has been long appreciated that expression of the Yersinia type-III secretion system (T3SS) in culture is associated with growth arrest. Here we sought to understand whether T3SS expression is sufficient to trigger loss of exponential phase markers, and utilized a fluorescent reporter for ribosomal protein expression to detect changes in bacterial growth state. Using a fluorescent transcriptional reporter with the rpsJ/S10 promoter fused to a destabilized gfp variant, we confirmed reporter expression significantly increases in exponential phase and decreases as cells transition to stationary phase. In a mouse model of systemic Y. pseudotuberculosis infection, we found multiple subsets of bacterial cells in the mouse spleen, including cells with high T3SS and low S10 expression and cells with high expression of both markers. In bacterial media, growth inhibition with T3SS induction and a reduction in S10 expression were observed, but a significant proportion of cells retained high expression of both T3SS and S10. Paradoxically, while loss of T3SS expression rescued growth, lower S10 expression was detected, again indicating bacteria can express both markers simultaneously. In media, bacteria grow planktonically as individual cells, while in mouse tissues, bacteria form clustered extracellular communities. We utilized droplet-based microfluidics to encapsulate bacteria in spherical agarose droplets and model clustered growth, and observed high expression of T3SS without an impact on S10 levels. Finally, we show that T3SS expression is sufficient to promote antibiotic tolerance, but surviving bacteria in a gentamicin treatment mouse model specifically express low S10. Collectively, these data indicate that the growth arrest associated with T3SS induction can reduce antibiotic susceptibility, but cells surviving antibiotic treatment display lower levels of the exponential phase marker, S10.

  • 3D Printed Spectroelectrochemical Platform for Redox‐Based Bioelectronics

    Small Methods · 2025-01-29 · 4 citations

    articleOpen accessSenior authorCorresponding

    Abstract Redox provides unique opportunities for interconverting molecular/biological information into electronic signals. Here, the fabrication of a 3D‐printed multiwell device that can be interfaced into existing laboratory instruments (e.g., well‐plate readers and microscopes) to enable advanced redox‐based spectral and electrochemical capabilities is reported. In the first application, mediated probing is used as a soft sensing method for biomanufacturing: it is shown that electrochemical signal metrics can discern intact mAbs from partially reduced mAb variants (fragmentation), and that these near‐real‐time electrical measurements correlate to off‐line chemical analysis. In the second application, operando spectroelectrochemical measurements are used to characterize a redox‐active catechol‐based hydrogel film: it is shown that electron transfer into/from the film correlates to the molecular switching of the film's redox state with the film's absorbance increasing upon oxidation and the film's fluorescence increasing upon reduction. In the final example, a synthetic biofilm containing redox‐responsive E. coli is electro‐assembled: it is shown that gene expression can be induced under reducing conditions (via reductive H 2 O 2 generation) or oxidative conditions (via oxidation of a phenolic redox‐signaling molecule). Overall, this work demonstrates that 3D printing allows the fabrication of bespoke electrochemical devices that can accelerate the understanding of redox‐based phenomena in biology and enable the detection/characterization redox activities in technology.

Recent grants

Frequent coauthors

  • Gregory F. Payne

    290 shared
  • Gregory F. Payne

    Institute for Bioscience and Biotechnology Research

    180 shared
  • Eunkyoung Kim

    148 shared
  • Reza Ghodssi

    University of Maryland, College Park

    123 shared
  • Rakesh Govind

    University of Maryland, Baltimore County

    117 shared
  • Chen‐Yu Tsao

    University of Maryland, College Park

    117 shared
  • Gary W. Rubloff

    97 shared
  • Yi Liu

    Beihang University

    94 shared

Awards & honors

  • Robert E. Fischell Distinguished Chair of Engineering (2016)
  • Charles Thom Award, Society of Industrial Microbiology and B…
  • Elected Fellow, American Chemical Society (ACS) (2013)
  • Elected Member, Electorate Nominating Committee, American As…
  • AIChE Food, Pharmaceutical and Bioengineering Division Award…
  • Resume-aware match score
  • Save to shortlist
  • AI-drafted outreach

See your match with William E. Bentley

PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.

  • Free to start
  • No credit card
  • 30-second signup